The 31 linked references in paper A. Kuzovlev N., V. Moroz V., A. Golubev M., S. Polovnikov G., А. Кузовлев Н, В. Мороз В, А. Голубев М, С. Половников Г. (2013) “Ингаляционные антибиотики в лечении тяжелой нозокомиальной пневмонии // Inhaled Antibiotics in the Treatment of Nosocomial Pneumonia” / spz:neicon:reanimatology:y:2013:i:6:p:61

  1. Bekaert M., Timsit J.F., Vansteelandt S., Depuydt P., Ve ́sin A., GarrousteOrgeas M., Decruyenaere J., Clec’h C., Azoulay E., Benoit D.; Outcomerea Study Group. Attributable mortality of ventilatorassociated pneumonia: a reappraisal using causal analysis. Am. J. Respir. Crit. Care Med.2011; 184 (10): 1133–1139. http://dx.doi.org/10.1164/rccm.2011050867OC. PMID: 21852541
  2. Valencia M., Torres A.Ventilator-associated pneumonia. Curr. Opin. Crit. Care. 2009; 15 (1): 30—35. http://dx.doi.org/10.1097/MCC. 0b013e3283220e78. PMID: 19186407
  3. Koulenti D., Lisboa T., Brun-Buisson C., Krueger W., Macor A., SoleViolan J., Diaz E., Topeli A., DeWaele J., Carneiro A., Martin-Loeches I., Armaganidis A., Rello J.; EU-VAP/CAP Study Group.Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit. Care Med.2009; 37 (8): 2360—2368. http://dx.doi.org/10.1097/CCM. 0b013e3181a037ac.PMID: 19531951
  4. Kuzovlev A., Polovnikov S., Stec V., Varvarin V.Efficacy of inhaled tobramycin in severe nosocomial pneumonia. Crit. Care.2012; 16 (Suppl 1): P71. http://dx.doi.org/10.1186/cc10678.
  5. Tamma P.D., Putcha N., Suh Y.D., Van Arendonk K.J., Rinke M.L.Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A metaanalysis and systematic review of randomized, controlled trials. BMC Infect. Dis.2011; 11: 181. http://dx.doi.org/10.1186/1471-2334-11-181. PMID: 21696619
  6. 3; 39 (6): 1048—1056. http://dx.doi.org/10.1007/s00134-0132872-5. PMID: 23525741 20.Palmer L.B.Aerosolized antibiotics in the intensive care unit. Clin. Chest Med.2011; 32 (3): 559—574. http://dx.doi.org/10.1016/j.ccm. 2011.05.012. PMID: 21867823
  7. Tolker-Nielsen T., Høiby N.Extracellular DNA and F-actin as targets in antibiofilm cystic fibrosis therapy. Future Microbiol.2009; 4 (6): 645—647. http://dx.doi.org/10.2217/fmb.09.38. PMID: 19659420
  8. Ioannidou E., Siempos I., Falagas M.Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J. Antimicrob. Chemother.2007; 60 (6): 1216—1226. http://dx.doi.org/10.1093/jac/dkm385. PMID: 17934205
  9. Hudson R., Olson Blair B.Inhaled antibiotics for Gram-negative respiratory infections. Future Med. Chem.2011; 3 (13): 1663—1677. http://dx.doi.org/10.4155/fmc.11.114. PMID: 21942255
  10. Le J., Ashley E.D., Neuhauser M.M., Brown J., Gentry C., Klepser M.E., Marr A.M., Schiller D., Schwiesow J.N., Tice S., VandenBussche H.L., Wood G.C.; Society of Infectious Diseases Pharmacists Aerosolized Antimicrobials Task Force. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy.2010; 30 (6): 562—584. http://dx.doi.org/10.1592/phco.30.6.562.PMID: 20500046
  11. Korbila I., Michalopoulos A., Rafailidis P.I., Nikita D., Samonis G., Falagas M.E. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilatorassociated pneumonia: a comparative cohort study. Clin. Microbiol. Infect.2010; 16 (8): 1230—1236. http://dx.doi.org/10.1111/j.14690691.2009.03040.x. PMID: 19732088
  12. Michalopoulos A., Fotakis D., Virtzili S., Vletsas C., Raftopoulou S., Mastora Z., Falagas M.E.Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med.2008; 102 (3): 407—412. A 25-fold increase over the minimal inhibitory concentration is required to overcome this inactivation. Changes of physico-chemical properties of IA during the aerosol formation due to heating, cooling, vibration, etc. (more profound in jet nebulizers), local and systemic toxic effects, bronchoconstrictive effects of conservatives should be noted. The bronchospasm is mostly induced by the inhaled colistin. Only special preparations for inhalation must be used to prev
  13. Michalopoulos A., Papadakis E.Inhaled anti-infective agents: emphasis on colistin. Infection. 2010; 38 (2): 81—88. http://dx.doi.org/ 10.1007/s15010-009-9148-6. PMID: 20191398
  14. Arnold H., Sawyer A., Kollef M.Use of Adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosaand Acinetobacter baumanniiventilator-associated pneumonia. Respir. Care. 2012; 57 (8): 1226—1233. http://dx.doi.org/10.4187/respcare.01556. PMID: 22349038
  15. Chuchalin A., Amelina E., Bianco F.Tobramycin for inhalation in cystic fibrosis: beyond respiratory improvements. Pulm. Pharmacol. Ther. 2009; 22 (6): 526—532. http://dx.doi.org/10.1016/j.pupt.2009.06.001. PMID: 19616111
  16. Drobnic M.E., SuñéP., Montoro J.B., Ferrer A., Orriols R.Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother.2005; 39 (1): 39—44. http://dx.doi.org/10.1345/aph. 1E099. PMID: 15562142
  17. Hallal A., Cohn S.M., Namias N., Habib F., Baracco G., Manning R.J., Crookes B., Schulman C.I.Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg. Infect. (Larchmt). 2007; 8 (1): 73—82. http://dx.doi.org/10.1089/sur.2006.051. PMID: 17381399
  18. Greally P., Whitaker P., Peckham D.Challenges with current inhaled treatments for chronic Pseudomonas aeruginosainfection in patients with cystic fibrosis. Curr. Med. Res. Opin.2012; 28 (6): 1059—1067. http://dx.doi.org/10.1185/03007995.2012.674500. PMID: 22401602
  19. Høiby N.Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med.2011; 9: 32. http://dx.doi.org/10.1186/1741-7015-9-32. PMID: 21463524
  20. Ghannam D.E., Rodriguez G.H., Raad I.I., Safdar A.Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis.2009; 28 (3): 253—259. http://dx.doi.org/10.1007/s10096-008-0620-5. PMID: 18752007
  21. Ratjen F., Munck A., Kho P., Angyalosi G.; ELITE Study Group. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax.2010; 65 (4): 286—291. http://dx.doi.org/10.1136/thx.2009.121657. PMID: 19996339
  22. Geller D.E., Flume P.A., Staab D., Fischer R., Loutit J.S., Conrad D.J.; Mpex 204 Study Group.Levofloxacin inhalation solution (MP—376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med.2011; 183 (11): 1510—1516. http://dx.doi.org/10.1164 /rccm.201008-1293OC. PMID: 21471106
  23. Lu Q., Yang J., Liu Z., Gutierrez C., Aymard G., Rouby J.J.; Nebulized Antibiotics Study Group.Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med.2011; 184 (1): 106—115. http://dx.doi.org/ 10.1164/rccm.201011-1894OC. PMID: 21474643
  24. Okusanya O.O., Bhavnani S.M., Hammel J., Minic P., Dupont L.J., Forrest A., Mulder G.J., Mackinson C., Ambrose P.G., Gupta R.Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother.2009; 53 (9): 3847—3854. http://dx.doi.org/ 10.1128/AAC.00872-08. PMID: 19451281
  25. Wainwright C.E., Quittner A.L., Geller D.E., Nakamura C., Wooldridge J.L., Gibson R.L., Lewis S., Montgomery A.B.Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P.aeruginosa. J. Cyst. Fibros.2011; 10 (4): 234—242. http://dx.doi.org/ 10.1016/j.jcf.2011.02.007. PMID: 21441078
  26. Trapnell B.C., McColley S.A., Kissner D.G., Rolfe M.W., Rosen J.M., McKevitt M., Moorehead L., Montgomery A.B., Geller D.E.; Phase 2FTI Study Group.Fosfomycin/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med. 2012; 185 (2): 171—178. http://dx.doi.org/10.1164/rccm.201105-0924OC. PMID: 22095545
  27. Herrmann G., Yang L., Wu H., Song Z., Wang H., Høiby N., Ulrich M., Molin S., Riethmüller J., Döring G.Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J. Infect Dis.2010; 202 (10): 1585—1592. http://dx.doi.org/10.1086/656788. PMID: 20942647
  28. MacLeod D.L., Barker L.M., Sutherland J.L., Moss S.C., Gurgel J.L., Kenney T.F., Burns J.L., Baker W.R.Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis.J. Antimicrob. Chemother. 2009; 64 (4): 829–836. http://dx.doi.org/10.1093/jac/dkp282. PMID: 19679597
  29. Ryan G., Jahnke N., Remmington T.Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Cochrane Database Syst Rev.2012; 12: CD008319. http://dx.doi.org/10.1002/14651858.CD008319.pub2. PMID: 23235659
  30. Lu Q., Luo R., Bodin L., Yang J., Zahr N., Aubry A., Golmard J.L., Rouby J.J.; Nebulized Antibiotics Study Group.Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosaand Acinetobacter baumannii. Anesthesiology. 2012; 117 (6): 1335–1347. http://dx.doi.org/10.1097/ALN. 0b013e31827515de. PMID: 3132092
  31. Chan E.Y., Ruest A., Meade M.O., Cook D.J.Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis. BMJ.2007; 334 (7599): 889. http://dx. doi.org/10.1136/bmj.39136.528160.BE. PMID: 17387118 Submited 19.08.13